Skip to main content
Calum Sutherland on Muck Rack

Calum Sutherland

As seen in: BMJ Open, The Conversation, The Japan Times, Medical Xpress, BioRxiv, Times of Malta, Artforum, Inner Self Magazine, Knowridge Science Report, Momus and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Calum

Contact Calum, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Elraglusib induces cytotoxicity via microtubule destabilisation independently of GSK3 inhibition

|
By Josh T Coats, Sudhir Tauro, Calum Sutherland, Adrian T. Saurin
| BioRxiv
Abstract Elraglusib (9-ING-41) is an ATP-competitive inhibitor of glycogen synthase kinase-3 (GSK3) with pre-clinical studies demonstrating broad activity against many tumour types. Promising early-phase clinical trial data led to FDA orphan drug status, and a randomised phase 2 study in combination with cytotoxic chemotherapy in pancreatic cancer has recently completed its recruitment.
Open in Who Shared Issue with article?

Elraglusib (formerly 9-ING-41) possesses potent anti-lymphoma properties which cannot be attributed to GSK3 inhibition

|
By Josh T Coats, Sudhir Tauro, Calum Sutherland, Coats JT
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (590) Issue with article?

Point-of-care testing of HbA1c levels in community settings for people with established diabetes or people at risk of developing type 2 diabetes: a systematic review and meta-analysis protocol

|
By Calum Sutherland, Andrew Radley, Anna Gourlay
| BMJ Open Verified
Methods and analysis This systematic review will be conducted according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidance.9 The PICOS statement developed for the study is: Population: those at risk of developing diabetes or those with established diabetes. Intervention: HbA1c testing using a POC device in a community setting. Comparison: POC testing compared with standard laboratory testing. Outcome: identifying, monitoring and managing diabetes.
Open in Who Shared Issue with article?
See all 33 articles